The pharmacokinetics and haemodynamics of BTS 49 465 and its major metabolite in healthy volunteers.
The pharmacokinetic and haemodynamic effects of a 200 mg oral dose of BTS 49 465 (7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone) were investigated in a double-blind placebo controlled study. BTS 49 465 was rapidly absorbed and cleared from the systemic circulation with a half-life of 1.6 h by oxidation to the sulphone metabolite. The metabolite was cleared with a half-life of 37.6 h. Saliva concentrations of both BTS 49 465 and its metabolite correlated well with the plasma concentrations. Compared to placebo, BTS 49 465 produced statistically significant reductions in blood pressure and increases in heart rate both supine and after a 60 degrees head up tilt. The time course of the haemodynamic changes suggested that the sulphone metabolite contributed to the overall hypotensive response. Plasma Renin Activity was only marginally elevated and there was no evidence of acute fluid retention. BTS 49 465 was well tolerated in terms of haematological and biochemical parameters and subjective side-effects.
D000284:Administration, Oral; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D004231:Diuresis / Q000187:drug effects; D004311:Double-Blind Method; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007700:Kinetics; D008297:Male; D011804:Quinolines / Q000009:adverse effects / Q000378:metabolism* / Q000494:pharmacology; D015363:Quinolones; D011897:Random Allocation; D012083:Renin / Q000097:blood; D012463:Saliva / Q000378:metabolism; D014665:Vasodilator Agents / Q000009:adverse effects / Q000378:metabolism* / Q000494:pharmacology
D011804:Quinolines; D015363:Quinolones; D014665:Vasodilator Agents; C047316:flosequinan; C047317:flosequinoxan; D012083:Renin